Invasive Pneumococcal Disease Epidemiology and Conjugate Vaccines in Canada, 2000-2019

What were the associations of the 7-valent pneumococcal conjugate vaccine (PCV7) and 13-valent PCV (PCV13) with incidence of invasive pneumococcal disease (IPD), and what future outcomes may be associated with PCV15, PCV20, and PCV21?In this cross-sectional study including 37 921 IPD isolates, PCV7 was associated with reducing IPD rates from PCV7 serotypes by 98.7% in children aged younger than 5 years and 88.4% in individuals aged 10 years and older, while PCV13 was associated with further reducing PCV13-only serotypes by 90.3% and 57.9% in these groups, respectively. Between 2015 and 2019, PCV15, PCV20, and PCV21 could have added 23% to 29%, 32% to 39%, and 36% to 49% coverage of observed IPD isolates, respectively.These findings suggest that newer PCVs may expand protection, but persistent and nonvaccine serotype IPD incidence emphasized the need for broader-spectrum vaccines.

Corresponding Author: Manish Sadarangani, BM, BCh, DPhil, Vaccine Evaluation Center, B.C. Children’s Hospital Research Institute, Vancouver, BC V5Z 4H4, Canada (msadarangani@bcchr.ubc.ca).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.